PAPILLON trial: Amivantamab plus chemotherapy adds months of survival in rare lung cancer
Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable ...
15 Sep 11:00 · Medical Xpress